Abcam, ab211285, Anti-KREMEN1 antibody - C-terminal

Size: 50µg
Rabbit Polyclonal KREMEN1 antibody. C-terminal. Suitable for IHC-P, WB and reacts with Human, Rat samples. Cited in 3 publications. Immunogen corresponding to Synthetic Peptide within Human KREMEN1.
Key facts
Host species:Rabbit,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Rat, Human,
Applications:WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Synthetic Peptide within Human KREMEN1. The exact immunogen used to generate this antibody is proprietary information.Q96MU8

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Immunogen, Storage buffer-pH: 7.4Preservative: 0.02% Sodium azideConstituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
KREMEN1 also known as Kringle Containing Transmembrane Protein 1 is a transmembrane protein with a mass of approximately 56 kDa. It acts as a receptor involved in the regulation of the Wnt-signaling pathway. This protein participates in modulating cellular functions and development. KREMEN1 expression occurs in various tissues with significant presence noted in the brain kidney and lung. Its role as an antagonist in the pathway marks its importance in maintaining cellular homeostasis.
Biological function summary
KREMEN1 interacts critically with other components of the Wnt pathway such as Dickkopf-1 (DKK1) to mediate cellular signaling. These interactions form a receptor complex with Lipoprotein receptor-related protein 6 (LRP6) which plays a significant role in inhibiting Wnt/beta-catenin signaling. This inhibition is important for processes such as cell differentiation and proliferation. KREMEN1's involvement in these processes highlights its contribution to controlling cellular behavior.
Pathways
KREMEN1 participates primarily in the Wnt signaling pathway. It regulates this pathway by affecting the LRP6 co-receptor in conjunction with DKK1. Another significant pathway involving KREMEN1 is the bone morphogenetic protein (BMP) signaling pathway. Here its interactions illustrate a complex interplay with proteins like noggin and chordin contributing to embryo development and bone formation processes.
Alterations in KREMEN1 expression or function can relate to cancer and bone disorders. In cancers aberrant Wnt signaling often facilitated through dysregulation of KREMEN1 and DKK1 interaction contributes to tumor development and progression. Bone developmental disorders such as osteoporosis may arise from disruptions in KREMEN1's role in bone morphogenetic protein pathways. Understanding KREMEN1's connection with these conditions proves important in therapeutic development and research.